Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shun-Qing Liang

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Science China. Life Sciences|November 6, 2023
All types of base conversions allowed by base editorsShun-Qing Liang, Wen Xue
Frontiers in Oncology|October 16, 2019
New Horizons in <i>KRAS</i>-Mutant Lung Cancer: Dawn After DarknessHaitang Yang, Shun-Qing Liang, Ralph A Schmid, et al.
RNA (New York, N.Y.)|August 24, 2019
Tissue-restricted genome editing in vivo specified by microRNA-repressible anti-CRISPR proteinsJooyoung Lee, Haiwei Mou, Raed Ibraheim, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 9, 2022
A flexible split prime editor using truncated reverse transcriptase improves dual-AAV delivery in mouse liverChunwei Zheng, Shun-Qing Liang, Bin Liu, et al.
Nature Biotechnology|April 5, 2022
A split prime editor with untethered reverse transcriptase and circular RNA templateBin Liu, Xiaolong Dong, Haoyang Cheng, et al.
Genes|July 29, 2025
Detecting Methylation Changes Induced by Prime EditingRonin Joshua S Cosiquien, Isaiah J Whalen, Phillip Wong, et al.
Nature Biotechnology|March 30, 2023
Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editingBowen Li, Rajith Singh Manan, Shun-Qing Liang, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
KRAS withdrawal in Cholangiocarcinoma leads to immune infiltration and tumor regressionYouwei Qiao, Matthew F Yee, Chaitanya N Parikh, et al.
Oncogenesis|August 22, 2019
HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancerHaitang Yang, Shun-Qing Liang, Duo Xu, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|December 3, 2025
KRAS Withdrawal in Cholangiocarcinoma Leads to Immune Infiltration and Tumor RegressionYouwei Qiao, Matthew F Yee, Chaitanya N Parikh, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Science China. Life Sciences|November 6, 2023
All types of base conversions allowed by base editorsShun-Qing Liang, Wen Xue
Frontiers in Oncology|October 16, 2019
New Horizons in <i>KRAS</i>-Mutant Lung Cancer: Dawn After DarknessHaitang Yang, Shun-Qing Liang, Ralph A Schmid, et al.
RNA (New York, N.Y.)|August 24, 2019
Tissue-restricted genome editing in vivo specified by microRNA-repressible anti-CRISPR proteinsJooyoung Lee, Haiwei Mou, Raed Ibraheim, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 9, 2022
A flexible split prime editor using truncated reverse transcriptase improves dual-AAV delivery in mouse liverChunwei Zheng, Shun-Qing Liang, Bin Liu, et al.
Nature Biotechnology|April 5, 2022
A split prime editor with untethered reverse transcriptase and circular RNA templateBin Liu, Xiaolong Dong, Haoyang Cheng, et al.
Genes|July 29, 2025
Detecting Methylation Changes Induced by Prime EditingRonin Joshua S Cosiquien, Isaiah J Whalen, Phillip Wong, et al.
Nature Biotechnology|March 30, 2023
Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editingBowen Li, Rajith Singh Manan, Shun-Qing Liang, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
KRAS withdrawal in Cholangiocarcinoma leads to immune infiltration and tumor regressionYouwei Qiao, Matthew F Yee, Chaitanya N Parikh, et al.
Oncogenesis|August 22, 2019
HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancerHaitang Yang, Shun-Qing Liang, Duo Xu, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|December 3, 2025
KRAS Withdrawal in Cholangiocarcinoma Leads to Immune Infiltration and Tumor RegressionYouwei Qiao, Matthew F Yee, Chaitanya N Parikh, et al.
Pageof 4